Navigation Links
Study Compares Safety of 'Biologic' Meds for Rheumatoid Arthritis
Date:8/8/2012

WEDNESDAY, Aug. 8 (HealthDay News) -- A new safety analysis of three powerful "biologic" drugs for rheumatoid arthritis finds no difference in terms of risk of death for the patients who use them.

The study was published Aug. 8 in the journal Arthritis & Rheumatism.

The three drugs studied include Humira, Enbrel and Remicade, all from a relatively new class of medications called TNF-alpha inhibitors. The Swedish research team note that early intervention with these drugs is now recommend to slow progression of rheumatoid arthritis, which causes painful inflammation in the joints.

However, "understanding risk versus benefits of treatment with the most commonly prescribed biologics is important for physicians and patients in managing rheumatoid arthritis," study lead author Dr. Julia Fridman Simard, of the Clinical Epidemiology Unit at the Karolinska Institute, in Stockholm, said in a journal news release.

One expert in the United States agreed.

Dr. Steven Carsons is chief of the division of rheumatology, allergy and immunology at Winthrop-University Hospital in Mineola, N.Y. He said that while there's been much "enthusiasm" for this class of drugs, it has "been tempered by concern for potentially serious side effects including infection and cancer. To date, there is debate among rheumatologists concerning the relative safety of individual TNF-alpha inhibitors."

In the new study, Simard's team compiled information on patients with rheumatoid arthritis who began treatment between 2003 and 2008. Of these patients, more than 1,600 started taking adalimumab (Humira), almost 2,700 were prescribed etanercept (Enbrel), and more than 2,000 began treatment with infliximab (Remicade).

During the five-year study, 211 of the patients died. However, the researchers found no difference in death rates among the three drugs.

According to Carsons, "it is reassuring that these authors found a mortality rate among TNF-alpha inhibitor-treated rheumatoid arthritis patients that was low ... similar to that found in prior clinical trials, and did not differ among the three TNF-alpha inhibitors studied. This information should assist rheumatologists and their patients when choosing among newer agents available to treat [the disease]."

However, the study authors stressed that more research may be needed to clarify risks for particular patients.

"While we found no statistically significant difference in mortality rates across the three biologic therapies, further studies are needed to determine if this is true across certain subsets of patients with rheumatoid arthritis," Simard concluded.

More information

The U.S. National Institutes of Health provides more information on rheumatoid arthritis.

-- Mary Elizabeth Dallas

SOURCE: Steven E. Carsons, M.D, chief, division of rheumatology, allergy and immunology, Winthrop-University Hospital, Mineola, N.Y.; Arthritis & Rheumatism, news release, Aug. 8, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Compares Safety of 'Biologic' Meds for Rheumatoid Arthritis 
(Date:10/13/2017)... ... ... As health professionals work to improve their approach to healthcare, there is ... than filling out a survey; in many cases health professionals and patients are working ... and research on the importance of active engagement with patients and members of the ...
(Date:10/13/2017)... Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD ... dose required and providing a CBD form that can be easily incorporated into liquid ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... Calif. , Oct. 10, 2017  NDS received FDA 510(k) ... — a medical-grade battery-powered display stand specifically designed for endoscopy environments. ... transform technology into a clinical solution to support the improvement of ... Innovative Design ... Mobile Wireless Solution ...
(Date:10/7/2017)...   Provista, a proven leader in the ... purchasing power, today announced a new resource area on ... is the online home for case studies, articles ... news releases, slideshows and events. ... resources at their fingertips, viewers can also watch short ...
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare product ... training aide "cprCUBE" on Kickstarter. The device will educate ... cardiac arrests with better efficiency compared to the dated ... real-time feedback on efficacy of the compression for a ... has a goal to raise $5,000. ...
Breaking Medicine Technology: